About lenvatinib mesilate eq to lenvatinib
Multi-targeted tyrosine kinase inhibitor
Used for
- Certain thyroid cancers that no longer respond to radioactive iodine
- Advanced kidney cancer, with pembrolizumab or everolimus
- Unresectable liver cancer
- Advanced endometrial cancer, with pembrolizumab
Usual adult dose
Usually 24 mg once daily for thyroid or endometrial cancer; 18 mg with everolimus or pembrolizumab for kidney cancer; liver-cancer dose depends on body weight.
Common side effects
- High blood pressure
- Diarrhea
- Tiredness and reduced appetite
- Nausea
Important warnings
- Can cause severe bleeding, heart problems, kidney or liver injury, and blood clots.
- May impair wound healing; treatment is usually paused before planned surgery.
- Can cause fetal harm; pregnancy testing and effective contraception are required.
- Blood pressure, urine protein, and thyroid function need monitoring.
Pregnancy
May harm an unborn baby. Avoid during treatment and for at least 30 days after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for at least one week after the last dose.
Interactions
- Everolimus and pembrolizumab are combination treatments for specific cancers.
- Medicines that prolong the QT interval may increase heart-rhythm risk.
- Some medicines affecting liver enzymes may alter lenvatinib exposure.
- NSAIDs and anticoagulants may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.